Cimzia is manufactured by UCB [1]. UCB is a global biopharmaceutical company headquartered in Belgium, with a focus on developing treatments for immunological and neurological diseases [1].
Who Else Makes Cimzia?
Currently, UCB is the sole manufacturer of Cimzia [1]. However, as patents for branded drugs expire, the landscape can change with the introduction of generic or biosimilar versions by other companies. Information on patent expirations and potential generic entry can be found at DrugPatentWatch.com [2].
When Does Cimzia's Patent Expire?
The patent expiration dates for Cimzia are complex and vary depending on the specific patent and region [2]. Different patents cover various aspects of the drug, including its formulation, method of use, and manufacturing processes. DrugPatentWatch.com provides detailed information on these patent landscapes [2].
What is Cimzia Used For?
Cimzia is a prescription medication used to treat adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease [3]. It is a tumor necrosis factor (TNF) blocker [3].
How Does Cimzia Work?
Cimzia works by blocking the action of a protein called tumor necrosis factor-alpha (TNF-alpha) [3]. TNF-alpha is a substance produced by the body's immune system that plays a role in inflammation. By blocking TNF-alpha, Cimzia helps to reduce inflammation, which can alleviate symptoms of conditions like rheumatoid arthritis and Crohn's disease [3].
What are the Side Effects of Cimzia?
Like all medications, Cimzia can cause side effects. Common side effects include upper respiratory tract infections, rash, and headache [3]. More serious side effects can include serious infections, allergic reactions, and nervous system problems [3]. Patients should discuss potential risks and benefits with their healthcare provider [3].
Can Cimzia Be Replaced by a Biosimilar?
The development of biosimilar versions of biologic drugs like Cimzia is possible once patents and market exclusivity have expired [2]. Biosimilars are highly similar to the original biologic drug in terms of safety, purity, and potency, and they are approved by regulatory agencies. DrugPatentWatch.com tracks the patent status that influences biosimilar entry [2].
Sources:
[1] https://www.ucb.com/
[2] https://drugpatentwatch.com/
[3] https://www.cimzia.com/